{'fraction_non_alphanumeric': 0.03697478991596639, 'fraction_numerical': 0.025210084033613446, 'mean_word_length': 4.753623188405797, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Inhibition by Tranilast of the Synergistic Induction of Degranulation and IL-13 Expression by IL-33 and FcɛRI Cross-linking in Mast Cells

ABSTRACT Purpose: To assess the effects of tranilast on degranulation and IL-13 production in mast cells activated by IL-33 and cross-linking of FcɛRI. Methods: Bone marrow-derived mast cells (BMMCs) were sensitized with anti-DNP IgE. Sensitized cells were pretreated with tranilast and further stimulated with DNP-BSA, IL-33, or a combination of DNP-BSA and IL-33. Degranulation and the level of IL-13 release and mRNA expression in BMMCs were measured. Results: Simultaneous stimulation with DNP-BSA and IL-33 resulted in marked increase in β-hexosaminidase release. Tranilast significantly inhibited degranulation of BMMCs in the condition of combined treatment of DNP-BSA and IL-33. Combination of DNP-BSA and IL-33 induced a pronounced increase in the IL-13 release and mRNA expression. Tranilast significantly inhibited IL-13 release and mRNA expression in BMMCs stimulated by DNP-BSA and IL-33. Conclusions: Tranilast has efficacy on the inhibition of degranulation and IL-13 production in BMMCs induced by the combination of DNP-BSA and IL-33.